Healthcare Equipment and Supplies
Company Overview of Teikoku Seiyaku Co., Ltd.
Teikoku Seiyaku Co., Ltd. engages in the development, manufacture, and sale of medicated and medically related supplies. It offers hot sensation, and analgesic and anti-inflammatory plasters; and Lidoderm, an analgesic plaster for the treatment of post-herpetic neuralgia. The company, through its subsidiaries, also engages in the research and development of transdermal products; and production and sale of medical adhesive products and external aqueous gel preparations. In addition, the company engages in the domestic marketing of non-prescription medicines, cosmetics, and other products; manufacturing and sale of Chinese herbal medicines; and production of fruit acids, such as malic acid for...
Founded in 1848
Key Executives for Teikoku Seiyaku Co., Ltd.
Chief Executive Officer, President and Director
Managing Director and Director
Senior Managing Director and Director
Senior Managing Director and Director
Compensation as of Fiscal Year 2016.
Teikoku Seiyaku Co., Ltd. Key Developments
Endo International Plc and Allergan Plc Units get Dragged to Court by US Federal Trade Commission Over Stifling Generic Competition
Apr 1 16
Endo International Plc and Allergan Plc announced that they have become the targets of a lawsuit launched by the US Federal Trade Commission (FTC), which alleges that subsidiaries of the two companies struck illegal agreements to delay the market entry of generic Opana ER and Lidoderm versions. The FTC filed its complaint on March 31, 2016, naming as guilty parties Endo Pharmaceuticals Inc, Allergan and its unit Watson Laboratories Inc, Impax Laboratories Inc, Teikoku Seiyaku Co Ltd. and Teikoku Pharma USA Inc. The two drugs at the centre of the complaint are Endo-branded products, Opana being an extended-release opioid painkiller and Lidoderm being a topical patch for relieving post-herpetic neuralgia pain. Impax and Watson were the first companies to seek approval from the US Food and Drug Administration for generic versions of these drugs. According to the FTC, Endo paid them to postpone the launch of the generic products and these so-called pay-for-delay settlements violate US antitrust laws. The complaint alleges that Endo and Impax entered into an illegal agreement in 2010, with the latter receiving more than USD 112 million (EUR 98.2 million) to hold off the launch of its Opana ER equivalent until January 2013. The amount included USD 10 million received by Impax as part of a development and co-promotion deal struck within that period. The illegal agreement with Watson over Lidoderm was signed in May 2012 and involved Endo partners Teikoku Seiyaku Co Ltd. and Teikoku Pharma USA Inc. as well. The FTC did not provide a specific figure for the payment received by Watson, saying only it amounted to hundreds of millions of dollars and the company pocketed a similar amount when it finally launched its generic version of the drug. This was the result of Endo's consent to refrain from selling an authorised Lidoderm generic version for seven and a half months, thus leaving Watson without any competition for a while.
Teikoku Seiyaku Co., Ltd. Presents at BIO-Europe 2015, Nov-02-2015
Oct 9 15
Teikoku Seiyaku Co., Ltd. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries